ERBB2 and breast carcinoma: In studies suggesting that PPARg has tumour-promoting effects, T0070907 has been proven to inhibit the formation of ERBB2-positive breast cancer cells into tumours [30], the growth of hepatocellular carcinoma cells [32] and the brain metastasis of melanoma [37].